|
|
[Home]
[Databases]
[WorldLII]
[Search]
[Feedback]
[Report an error]
[F.A.Q.]
Vanuatu Consolidated Legislation |
Commencement: 27 August 1966
LAWS
OF THE REPUBLIC OF
VANUATU
REVISED
EDITION 1988
CHAPTER 48
SALE OF MEDICINES (CONTROL)
JR
32 of 1966
Act 9 of
1988
ARRANGEMENT OF SECTIONS
SECTION
1. Interpretation
2. Limitation
on the retail sale of medicines
3. Limitation on the wholesale sale of medicines
4. Sale of narcotics
5. Control of price
6. Inspection of premises
7. Regulations
8. Penalties
9. Application
-----------------------------------------
SALE OF MEDICINES (CONTROL)
To
control the sale of
medicines.
INTERPRETATION
1. In
this Act, unless the context otherwise requires -
"medicine" means any substance which is referred to in the article itself, or in advertisements or documents of any kind in terms calculated to lead to the use of the substance for the prevention or treatment of any ailment, infirmity or injury afflicting the human body;
"pharmacist" means a person holding a licence issued by the Pharmacists Practitioners Commission as provided for by the Control of Pharmacists Act, Cap. 23;
"medical or dental practitioner" means a medical or dental practitioner registered in accordance with the provisions of the Health Practitioners Act, Cap. 164;
"Minister" means the Minister responsible for health;
"veterinary surgeon" means a person authorised by the Minister, by reason of his qualifications, to act as such;
"druggist" means a person who shall have obtained from the Pharmacists Practitioners Commission a licence authorising him to sell medicines under the conditions prescribed in this Act and outside the zone protecting a pharmacist.
LIMITATION
ON THE RETAIL SALE OF
MEDICINES
2. (1) When
a pharmacist has his principal place of business in any place within
Vanuatu,
no person other than a pharmacist shall operate a drug-store within 5 miles of that place of business.
(2) Outside this zone and subject to their observing international legislation, in particular legislation prohibiting anyone other than a pharmacist from selling narcotics, druggists may sell the same medicines as a pharmacist.
LIMITATION
ON THE WHOLESALE SALE OF
MEDICINES
3. (1) No
person shall sell wholesale any medicine other than those as may be
prescribed
under section 7(l) to any person other than a pharmacist or druggist.
(2) Any importation of medicines shall be recorded by the Director of Customs who shall send a list thereof to the Director of Health.
SALE
OF NARCOTICS
4. No person other than a pharmacist shall have in his possession, import, sell or otherwise deal in any of the substances subject to the Regulations of the Permanent Opium Committee:
Provided that a person shall be lawfully in possession of the substances aforesaid if he is in such possession by virtue of a medical prescription.
CONTROL
OF PRICE
5. The Minister may by Order take such measures as he may deem necessary to control the sale price of medicines.
INSPECTION
OF
PREMISES
6. (1) Every
member of the Department of Health or any other person authorised in
that
behalf by the Director of Health shall, for the purpose of ensuring that the provisions of this Act have been complied with, have the right of access to any premises on which he reasonably suspects that such provisions are not being so complied with.
(2) Any person who obstructs any member of the Department of Health or any person authorised under the provisions of subsection (1) in or upon the occasion of the execution of his duty under this Act shall be guilty of an offence and on conviction thereof shall be liable to a fine not exceeding VT20,000.
REGULATIONS
7 (1) The
Minister may by Order make regulations not inconsistent with the
provisions
of this Act -
(a) regulating the sale of medicines; or
(b) prohibiting the sale of any medicines except upon the prescription of a medical practitioner or dental practitioner or veterinary surgeon.
(2) Any regulation made under subsection (1) may authorize the Principal Pharmacist to make and issue notices or directives with respect to such matters prescribed by that regulation.
PENALTIES
8. (1) Any
person who acts in contravention of sections 2 and 3 shall be guilty of
an
offence and on conviction thereof shall be liable to a fine not exceeding VT50,000 or to a term of imprisonment not exceeding 1 year or to both such fine and imprisonment.
(2) Any person who acts in contravention of section 4 shall be guilty of an offence and on conviction thereof shall be liable to a fine not exceeding VT100,000 or to a term of imprisonment not exceeding 2 years or to both such fine and imprisonment.
APPLICATION
9. Notwithstanding the provisions of this Act the Minister may, by Order, authorise the health service, hospitals and clinics (public or private), to sell medicines under the same conditions as a pharmacist or a druggist, and the conditions governing distance provided for in section 2(2) shall not apply to them.
_____________________
[Subsidiary]
SUBSIDIARY LEGISLATION
SALE OF MEDICINES REGULATIONS
Order 25 of 1988
ARRANGEMENT OF REGULATIONS
REGULATION
1. Interpretation
2. Sale of medicines
3. Notices
SCHEDULE
1
SCHEDULE
2
SCHEDULE
3
----------------------------------------
SUBSIDIARY LEGISLATION
SALE OF MEDICINES REGULATIONS
To
regulate the sale of
medicines.
INTERPRETATION
1. In
these regulations unless the context otherwise requires "child-resistant
closure" means -
(a) a closure which is resistant to opening by children;
(b) in the case of a can fitted with a press-on lid, a lid of the design known as "double tight" or "triple tight";
"dosage unit" means an individual dose of a medicine and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules;
"internal use" means administration -
(a) orally, except for topical effect in the mouth; or
(b) for absorption and the production of a systemic effect -
(i) by way of a body orifice other than the mouth; or
(ii) parenterally, other than by application to unbroken skin.
"medicine" means any substance or preparation which is included in the Schedules;
"primary pack" means the pack in which a medicine and its immediate container or immediate wrapper or measure pack are presented for sale or supply; and -
(a) "immediate container" includes all forms of containers in which a medicine is directly packed but does not include any such container intended for consumption or any immediate wrapper;
(b) "immediate wrapper" means metal foil, plastic foil, waxed paper, or any such material not intended for consumption, when used as the first wrapper for a dosage unit which contains any medicine;
(c) "measure pack" means one of two or more sealed containers each of which contains a measured quantity of medicine for use on one occasion as a pesticide and which forms part of a single primary pack;
"therapeutic use" means use in or in connection with -
(a) the preventing, diagnosing, curing or alleviating of a disease, ailment, defect or injury in human beings or animals;
(b) the influencing, inhibiting or modifying of a physiological process in human beings or animals; or
(c) the testing of the susceptibility of human beings or animals to a disease or ailment;
"topical use" means application of a medicine for the purpose of producing a localised effect on the surface of the organ or within the issue to which it is applied.
SALE
OF
MEDICINES
2. (1) Any
person may sell any of the medicines specified in Schedule 1.
(2) No person, other than a pharmacist or a druggist, shall sell any of the medicines specified in Schedule 2.
(3) No person shall sell the medicines specified in Schedule 3, except upon the prescription of is a medical practitioner, dental practitioner or a veterinary surgeon.
NOTICES
3. (1) The
Principal Pharmacist may issue such notices as he deems fit for the
proper
carrying out of these regulations.
(2) Any notice issued under this regulation shall be published in the Gazette.
___________________
SCHEDULE 1
ACETIC
ACID (excluding its salts and derivatives) and preparations containing more than
80 per cent of acetic acid, for therapeutic
use.
ALOXIPRIN
AMMONIATED
MERCURY
ANTAZOLINE
in eye
drops.
ASPIRIN
except
-
(a) when
included in Schedule 3;
(b) in individually wrapped powders or sachets of granules each containing 650 milligrams or less of aspirin as the only therapeutically active constituent when -
(i) the pack is labelled with the warning statement -
WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii) in a primary pack containing not more than 12 such powders or sachets of granules; or
(c) tablets or capsules each containing 325 milligrams or less of aspirin as the only therapeutically active constituent when -
(i) the pack is labelled with the warning statement -
WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and
(iii) in a primary pack containing not more than 25 such tablets or capsules.
ATROPINE,
except atropine methonitrate included in Schedule 3 -
(a) in preparations containing 0.25 per cent or less of atropine; or
(b) atropine sulphate, 0.6 mg tablets in packs of 6, when labelled for treatment of organophosphorus poisoning.
BELLADONNA
in preparations containing 0.25 per cent less or less of the alkaloids of
belladonna, calculated as
hyoseyamine.
BENZAMINE
when included in -
(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of benzamine in each;
(b) suppositories
or bougies containing 200 mg or less of benzamine in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of benzamine.
BENZOCAINE
when included in -
(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of benzocaine in each;
(b) suppositories
or bougies containing 200 mg or less of benzocaine in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of benzocaine.
BENZOYL
PEROXIDE in preparations for external human thereapeutic use containing 5 per
cent or less benzoyl
peroxide.
BENZYDAMINE
in preparations for tropical use containing 3 per cent or less of
benzydamine.
BROMHEXINE
BROMPHENIRAMINE
when compounded with one or more of the following medicaments -
(a) an antitussive except codeine or dihydrocodeine;
(b) an
expectorant;
or
(c) a
sympathomimetic
amine;
except
in preparations for the treatment of children under 2 years of
age.
BUCLIZINE
in primary packs of 10 doses or less, for the prevention or treatment of motion
sickness.
BUTYLAMINOBENZOATE
when included in -
(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of butylaminobenzoate in each;
(b) suppositories
or bougies containing 200 mg or less of butylaminobenzoate in each;
or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of butyla- minobenzoate.
CARBARYL
in preparations for external human therapeutic use containing 2 per cent or less
of
carbaryl.
CARBENOXOLONE
for topical oral
use.
CAR.BETAPENTANE
except in preparations containing 0.5 per cent or less of carbetapentane.
CHLOROFORM in preparations for therapeutic
use except
-
(a) when
included in Schedule 3;
or
(b) in
preparations containing 0.5 per cent or less of
chloroform.
CHLORPHENIRAMINE
when compounded with one or more of the following medicaments -
(a) an antitussive except codeine or dihydrocodeine;
(b) an
expectorant;
or
(c) a
sympathomimetic
amine;
except
in preparations for the treatment of children under 2 years of
age.
CINNAMEDRINE
CLIOQUINOL
and other halogenated derivatives of 8-Hydroxyquinoline for external human use.
CODEINE -
(a) when compounded with aspirin, paracetamol or salicylamide or any one of their derivatives, in tablets or capsules each containing 10 mg or less of codeine, and no other analgesic substance, when -
(i) packed in blister or strip packaging or in containers with child-resistant closures; and
(ii) in a primary pack containing 25 or less dosage units; or
(b) when
compounded with one or more other therapeutically active substances
-
(i) in divided preparations containing 10 mg or less per dosage unit of codeine and with a recommended dose not exceeding 15 mg of codeine; or
(ii) in undivided preparations containing 0.25 per cent or less of codeine and with a recommended dose not exceeding 15 mg of codeine.
CREOSOTE,
for therapeutic use, except in preparations containing 3 per cent or less of
phenois included in Schedule
1.
CYANIDES-see
hydrocyanic
acid.
DDT-see
dicophane.
DEXCHLORPHENIRAMINE
when compounded with one or more of the following medicaments-
(a) an antitussive except codeine or dihydrocodeine;
(b) an
expectorant;
or
(c) a
sympathomimetic
amine;
except
in preparations for the treatment of children under 2 years of
age.
DEXTROMETHORPHAN
when compounded with one or more other therapeutically active sub- stances in
such a way that the dextromethorphan
contained therein cannot be readily
extracted, when -
(a) in divided preparations containing 30 mg or less per dosage unit and with a recommended dose not exceeding 30 mg of dextromethorphan; or
(b) in undivided preparations containing 0.3 per cent or less of dextromethorphan with a recommended dose not exceeding 30 mg of dextromethorphan.
TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL)
AMINO) CYCLOHEXANOL HYDROCHLORIDE MONOHYDRATE (Sputolysin) in oral preparations
for the treatment
of
animals.
DICOPHANE
(DDT) in preparations for human therapeutic
use.
DICYCLOMINE
in preparations containing 0. I per cent or less of
dicyclomine.
DIMENHYDRINATE
in primary packs of 10 doses or less, for the prevention or treatment of motion
sickness.
DIMETHISOQUIN
in preparations for topical
use.
DIPHEMANIL
METHYLSULPHATE in preparations for topical
use.
DIPHENHYDRAMINE
-
(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b) when compounded with one or more of the following medicaments -
(i) an antitussive except codeine or dihydrocodeine;
(ii) an expectorant; or
(iii) a sympathomimetic aniine;
except in preparations for the treatment of children under 2 years of age.
DIPHENYLPYRA,LINE
when compounded with one or more of the following medicaments -
(a) an antitussive except codeine or dihydrocodeine;
(b) an
expectorant;
or
(c) a
sympathomimetic
aniine;
except
in preparations for the treatment of children under 2 years of
age.
DOXYLAMINE
when compounded with one or more of the following medicaments
-
(a) an
antitussive except codeine or
dihydrocodeine;
(b) an
expectorant;
or
(c) a
sympathomimetic
amine;
except
in preparations for the treatment of children under 2 years of
age.
EPHEDRINE
for internal use, when compounded with one or more other therapeutically active
substances in preparations containing 30
mg or less of ephedrine per recommended
dose, other than preparations for stimulant, appetite suppression or weight
control purposes,
except in liquid preparations containing 10 mg or less of
ephedrine per recommended
dose.
ERYTHRITYL
TETRANITRATE for therapeutic
use.
ETAFEDRINE
ETHER
for therapeutic use except -
(a) when
included in Schedule 3; or
(b) in preparations containing 10 per cent or less of ether.
ETHOHEPTAZINE
in preparations containing 1 per cent or less of
ethoheptazine.
ETHYLMORPHINE,
when compounded with one or more other therapeutically active substances
-
(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of ethylmorphine; or
(b) in undivided preparations containing 0.25 per cent or less of ethylmorphine with a recommended dose not exceeding 15 mg of ethylmorphine.
FLUORIDES
for human therapeutic use -
(a) sodium fluoride, in preparations for ingestion containing 2.2 mg or less of sodium fluoride per dosage unit, or
(b) in
preparations for topical use except -
(i) in dentifrices containing 1,000 mg/kg or less of fluoride ion; or
(ii) in substances containing 15 mg/kg or less of fluoride ion.
GELSEMIUM
GLUTARALDEHYDE
for human therapeutic
use.
GLYCERYL
TRINITRATE for therapeutic use except when included in Schedule
3.
GUAIPHENESIN
-
(a) in liquid preparations containing 2 per cent (200 mg/10 ml) or less of guaiphenesin; or
(b) in
divided preparations containing 120 mg or less of guaiphenesin in each dosage
unit.
HEXACHLOROPHANE
in preparations for human skin cleansing purposes containing 3 per cent or less
of hexachlorophane except in preparations
for use on infants as specified in
Schedule
3.
HOMATROPINE
in preparations containing 0.25 per cent or less of
homatropine.
HUMAN
CHORIONIC GONADOTROPHIN OR ANTIBODY in pregnancy test
kits.
HYDROCYANIC
ACID and CYANIDES in preparations for therapeutic use containing the equivalent
of 0. 15 per cent or less of hydrocyanic
acid.
8-HYDROX'YQUINOLINE
and its non-halogenated derivatives for human therapeutic use, except in
preparations for external use containing
1 per cent or less of such
substances.
HYOSCINE,
except hyoseine butylbromide included in Schedule 3 -
(a) in preparations containing 0.25 per cent or less of hyoscine; or
(b) in transdermal applicators containing 2 mg or less of hyoscine.
HYOSCYAMINE
in preparations containing 0.25 per cent or less of
hyoseyamine.
HYOSCYAMUS
in preparations containing 0.25 per cent or less of the alkaloids of hyoscyamus
calculated as
hyoseyamine.
IODINE
(excluding its salts, derivatives and iodophors), in preparations for human
therapeutic use containing more than 2.5 per cent
of available
iodine.
IRON
COMPOUNDS for human internal use except
-
(a) when
included in Schedule
3;
(b) in
divided preparations containing 5 mg or less of iron per dosage unit;
or
(c) in
liquid oral preparations containing 0.1 per cent or less of
iron.
ISOPROPAMIDE
in preparations containing 2 per cent or less of isopropamide for cutaneous
use.
ISOSORBIDE
DINITRATE for therapeutic
use.
LIGNOCAINE
when included in -
(a) lozenges, pastilles, tablets or capsules containing 30 mg or less of lignocaine in each;
(b) suppositories or bougies containing 200 mg or less of lignocaine in each; or
(c) preparations for external use, other than eye drops, containing 10 per cent or less of lignocame.
LINDANE
in preparations for external human therapeutic use containing 2 per cent or less
of
lindane.
LOBELIA
in preparations containing 0.5 per cent or less of lobeline, except in
preparations for smoking or
burning.
LUTEINISING
HORMONE ANTIBODIES in human ovulation test
kits.
MALDISON
in preparations for external human therapeutic use containing 2 per cent or less
of
maldison.
MEBENDAZOLE
for human therapeutic
use.
MERCURIC
CHLORIDE in preparations containing 0.5 per cent or less of mercuric chloride,
except when included in a
notice.
MERCURIC
IODIDE in preparations for therapeutic use containing 2 per cent or less of
mercuric
iodide.
MERCURIC
NITRATE in preparations for therapeutic use containing 5 per cent or less of
mercuric
nitrate.
MERCURIC
OXIDE and all oxides of
mercury.
MERCURIC-POTASSIUM
IODIDE in preparations containing the equivalent of 2 per cent or less of
mercuric iodide, in such
form.
MERCURY
(metallic) for therapeutic
use.
MERCURY
ORGANIC COMPOUNDS for topical therapeutic use in preparations containing 0.5 per
cent or less of
mercury.
METHOXAMINE
except
-
(a) preparations
containing 0.5 per cent or less of methoxamine; or
(c) preparations for external use containing 1 per cent or less of methoxamine.
METHOXYPHENAMINE
METHYLEPHEDRINE
NAPHAZOLINE
NICLOSADINE
for human therapeutic
use.
NITRIC
ESTERS of polyhydric alcohols for therapeutic use except when separately
specified in these
Schedules.
NOSCAPINE
OXETHAZAINE
in preparations for internal use
only.
OXOLAMINE
OXYMETAZOLINE
PAPAVERINE
PARACETAMOL
except
-
(a) when
included in Schedule 3;
(b) in individually wrapped powders or sachets of granules each containing 1,000 milligrams or less of paracetamol as the only therapeutically active constituent when -
(i) the pack is labelled with the warning statement -
WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii) in a primary pack containing not more than 12 such powders or sachets of granules; or
(c) tablets or capsules each containing 500 milligrams or less of paracetamol as the only therapeutically active constituent when -
(i) the pack is labelled with the warning statement -
WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and
(iii) in a primary pack containing not more than 25 such tablets or capsules.
PHEDRAZINE
PHENAMAZOLINE
PHENAZONE
for external
use.
PHENIRAMINE
-
(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b) when compounded with one or more of the following medicaments -
(i) an antitussive except codeine or dihydrocodeine;
(ii) an expectorant; or
(iii) a sympathomimetic amine;
except
in preparations for the treatment of children under 2 years of
age.
PHENOL
and any homologue of phenol boiling between 220 C, for human therapeutic use,
except in preparations containing 3 per cent
or less by weight of such
substances.
PHENYLENEDIAMINES
and alkylated phenylenediamines for therapeutic
use.
PHENYLEPHRINE
except
-
(a) when
included in Schedule
3;
(b) preparations
containing 0.5 per cent less of phenylephrine;
or
(c) preparations
for external use containing 1 per cent or less of
phenylephrine.
PHOLCODINE,
when compounded with one or more other therapeutically active substances
-
(a) in divided preparations containing 10 mg or less of pholeodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine; or
(b) in undivided preparations containing 0.5 per cent or less of pholcodine and with a recom- mended dose not exceeding 25 mg of pholcodine.
PODOPHYLLUM
RESIN (podophyllin) for external human use in preparations containing 10 per
cent or less of
Oodophyllin.
POTASSIUM
CHLORATE for therapeutic use except in preparations containing 10 per cent or
less of potassium
chlorate.
PRAMOXINE
when included in preparations for external use, other than eye drops, containing
1 per cent or less of
pramoxine.
PROCYCLIDINE
in preparations containing 5 per cent or less of procyclidine for cutaneous use.
PROMETHAZINE -
(a) in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b) when
compounded with one or more of the following medicaments -
(i) an antitussive except codeine or dihydrocodeine;
(ii) an expectorant; or
(iii) a sympathomimetic amine,
except
in preparations for the treatment of children under 2 years of
age.
PROPANTHELINE
in preparations for topical
use.
PROPYLHEXEDRINE
in appliances for inhalation in which the substance is absorbed upon an inert
solid
material.
PSEUDOEPHEDRINE
except when included in Schedule 3 -
(a) in divided preparations containing 60 mg or less of pseudoephedrine per recommended dosage unit; or
(b) in liquid preparations containing 60 mg or less of pseudoephedrine per recommended adult dose.
PYRANTEL
for human therapeutic
use.
PYRITHIONE
ZINC for human therapeutic use, except in preparations containing 2 per cent or
less of pyrithione zinc, when -
(a) in semisolid hair preparations; or
(b) in
shampoos.
SALICYLAMIDE
except
-
(a) when
included in Schedule 3;
(b) in individually wrapped powders or sachets of granules each containing 1,000 milligrams or less of salicylamide as the only therapeutically active constituent when -
(i) the pack is labelled with the warning statement -
WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii) in a primary pack containing not more than 12 such powders or sachets of granules; or
(c) tablets or capsules each containing 500 milligrams or less of salicylamide as the only therapeutically active constituent when -
(i) the pack is labelled with the warning statement -
WARNING-THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION-THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii) packed in blister or strip packaging or in containers with a child-resistant closure; and
(iii) in a primary pack containing not more than 25 such tablets or capsules.
SILVER
SALTS for therapeutic use, except -
(a) chewing tablets containing 5 mg or less of silver per tablet; or
(b) solutions containing 0.3 per cent or less of silver.
SODIUM
NITRITE for therapeutic
use.
SPUTOLYSIN-See
trans -4-((3,5-dibromo-2-hydroxybenzyl)-amino) cyclohexanol hydrochloride
monohydrate.
STAPHISAGRIA
except in preparations containing 0.2 per cent, or less of
staphisagria.
STRAMONIUM
in preparations containing 0.25 per cent or less of the alkaloids calculated as
hyoscyamine, except preparations for smoking
or
burning.
TETRAHYDROZOLINE
THENYLDIAMINE
(a) in
nasal preparations for topical use;
or
(b) when
compounded with one or more of the following medicaments -
(i) an antitussive except codeine or dihydrocodeine;
(ii) an expectorant; or
(iii) a sympathomimetic amine,
except in preparations for the treatment of children under 2 years of age.
TRAMAZOLINE
TRIMEPRAZINE
when compounded with one or more of the following medicaments -
(a) an antitussive except codeine or dihydrocodeine;
(b) an expectorant; or
(c) a
sympathomimetic amine,
except in preparations for the treatment of children under 2 years of age.
TRIPROLIDINE
when compounded with one or more of the following medicaments -
(a) an antitussive except codeine or dihydrocodeine;
(b) an
expectorant;
or
(c) a
sympathomimetic amine,
except in preparations for the treatment of children under 2 years of age.
TYMAZOLINE
XYLOMETAZOLINE
______________________
SCHEDULE 2
ACEPIFYLLINE
in liquid oral
preparations.
ADRENALINE
in preparations containing 1 per cent or less of adrenaline except in
preparations containing 0.02 per cent or less of
adrenaline.
AMINOPHYLLINE
in liquid oral
preparations.
AMYL
NITRITE
BENZOYL
PEROXIDE in preparations containing 10 per cent or less of benzoyl peroxide for
external human therapeutic use, except when
included in Schedule
1.
BROMPHENIRAMINE
in oral preparations except when included in Schedule
1.
BUCLIZINE
in oral preparations except when included in Schedule
1.
BUTYL
NITRITE
CHLORAL
HYDRATE for human internal therapeutic use in preparations containing 5 per cent
or less of chloral hydrate, when packed in
containers of 100 ml or
less.
CHLOROFLUOROCARBONS-See
FLUOROCARBONS
CHLORPHENIRAMINE
in oral preparations except when included in Schedule
1.
CLEMASTINE
in oral
preparations.
CLOTRIMAZOLE
for human use in preparations containing 1 per cent or less of clotrimazole, for
treatment of fungal infections of the
skin.
CODEINE
in tablets or capsules each containing 10 mg or less of codeine when compounded
with aspirin, paracetamol or salicylamide
or any one of their derivatives and no
other analgesic substance, except when included in Schedule
1.
CYPROHEPTADINE
in oral
preparations.
DEXCHLORPHENIRAMINE
in oral preparations except when included in Schedule
1.
DIHYDROCODEINE,
when compounded with one or more other therapeutically active substances when
-
(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine.
DIMENHYDRINATE
in oral preparations except when included in Schedule
1.
DIMETHINDENE
in oral
preparations.
DIPHENHYDRAMINE
in oral preparations except when included in Schedule
1.
DIPHENYLPYRAILINE
in oral preparations except when included in Schedule
1.
DITHRANOL
for human therapeutic
use.
DOXYLAMINE
in oral preparations except when included in Schedule
1.
ECONAZOLE
for human use in preparations containing 1 per cent or less of econazole for
treatment of fungal infections of the
skin.
EPHEDRINE
for internal use when compounded with one or more other therapeutically active
substances, other than preparations for stimulant,
appetite supression or weight
control purposes, except
-
(a) when
included in Schedule 1;
or
(b) in
liquid preparations containing 10 mg or less of ephedrine per recommended
dose.
FENOTEROL
in metered aerosols delivering 200 micrograms or less of fenoterol per metered
dose.
FELAVOXATE
FLUOROCARBONS
and CHLOROFLUOROCARBONS alone or in combination with other propellants or
refrigerants in liquefied gas form for therapeutic
use.
FOLIC
ACID for human therapeutic use except in preparations containing 500 micrograms
or less of folic acid per recommended daily
dose.
FOLINIC
ACID for human therapeutic use except in preparations containing 500 micrograms
or less of folinic acid per recommended daily
dose.
HYDROCORTISONE
and HYDROCORTISONE ACETATE as the only therapeutically active substances in
preparations for dermal use containing
0.5 per cent or less of hydrocortisone in
packs containing 30 grams or less where the labelling warns against contact with
the eyes
and against use for acne and on children below 2 years of age, use
beyond 7 days, and use under occlusive dressings, except on medical
advice.
IDOXURIDINE
in preparations containing 0.5 per cent or less of idoxuridine for cutaneous
use.
INSULIN
ISOCONAZOLE
for human use in preparations containing 1 per cent or less of isoconazole, for
treatment
of fungal infections of the
skin.
LOPERAMIDE
in packs of 8 dosage units or less, each dosage unit containing 2 mg or less of
loperamide.
MEFENAMIC
ACID in packs of 30 or less capsules for treatment of spasmodic
dysmenorrhoea.
MEPYRAMINE
in oral
preparations.
METHDILAZINE
in oral
preparations.
MICONAZOLE
for human use in preparations containing 2 per cent or less of miconazole for
treatment of fungal infections of the
skin.
NAPROXEN
in packs of 12 or less tablets for capsules, for treatment of spasmodic
dysmenorrhoea.
NITROPFURAZONE
in preparation for cutaneous use containing 0.2 per cent or less of
nitrofurazone.
OCTYL
NITRITE
PHENIRAMINE
in oral preparations except when included in Schedule
1.
PHENYLPROPANOLAMINE
in preparations for relief of coughs or colds, containing 25 mg or less per dose
of
phenylpropanolamine.
PHENYLTOLOXAMINE
in oral
preparations.
PODOPHYLLUM
RESIN (Podophyllin) for external human use in preparations containing 20 per
cent or less of podophyllin except when included
in Schedule
1.
PROMETHAZINE
in oral preparations except when included in Schedule 1. PSEUDOEPHEDRINE except
when included in Schedule 1 or
3.
QUININE
for human internal therapeutic use except in liquids containing 40 mg/L or less
of is
quinine.
SALBUTAMOL
(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
(b) in capsules of dry powder for inhalation delivering 200 micrograms or less of salbutamol per dose.
SANTONIN
SODIUM
CROMOGLYCATE in nasal preparations for topical
use.
TERBLTTALINE.in
metered aerosols delivering 250 micrograms or less of terbutaline per metered
dose.
THENYLDIAMINE
in oral preparations except when included in Schedule
1.
THEOPHYLLINE
in liquid oral
preparations.
TIOCONAZOLE
for human use in preparations containing 1 per cent or less of tioconazole, for
treatment of fungal infections of the
skin.
TRETINOIN
for external human therapeutic
use.
TRIMEPRAZINE
(a) in
solid oral preparations; or
(b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mi. except when included in Schedule 1.
TRIPROLIDINE
in oral preparations except when included in Schedule 1.
_________________________
SCHEDULE 3
(Substances
marked + are listed in the
Notice)
ACEBUTOLOL
ACEPIFYLLINE
except when included in Schedule
2.
ACEPROMAZINE
ACETANILIDE
and alkyl acetanilides, for human therapeutic
use.
ACETAZOLAMIDE
ACETOHEXAMIDE
ACETYLCHOLINE
and other choline esters except when separately specified in this
Schedule.
ACETYLCYSTEINE
ACETYLDIHYDROCODEINE,
when compounded with one or more other medicaments -
(a) in divided preparations containing not more than 100 mg of acetyldihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of acetyldihy drocodeine.
ACETYLMETHYLDIMETRYLOXIMIDOPHENYLHYDRAZINE
ACYCLOVIR
ADIPHENINE
ADRENALINE
except
-
(a) when
included in Schedule 2;
or
(b) in
preparations containing 0.02 per cent or less of
adrenaline.
ALCURONIUM
alpha-CHLORALOSE-See
chloralose.
ALPHADOLONE
ALPHAXALONE
ALPRAZOLAM
ALPRENOLOL
ALPROSTADIL
AMANTADINE
AMBENONIUM
AMBUCETAMIDE
AMBUTONIUM
AMETHOCAINE
AMIKACIN
AMILORIDE
AMINOCAPROIC
ACID
AMINOGLUTEMMIDE
AMINOMETRADINE
AMINOPHENAZONE
and derivatives therefrom for the treatments of
animals.
AMINOPHYLLINE
except when included in Schedule
2.
AMINOPTERIN
AMINOREX
AMIODARONE
AMIPHFNAZOLE
AMISOMETRADINE
AMITRIPTYLINE
and other compounds structurally derived therefrom by substitution in the side
chain except when separately specified
in this
Schedule.
AMODIAQUINE
AMOXYCILLIN
AMPHOMYCIN
AMPHOTERICIN
AMPICILLIN
AMSACRINE
AMYLOBARBITONE
when packed and labelled for
injection.
AMYLOCAINE
ANABOLIC
STEROIDAL AGENTS except when separately specified in this
Schedule.
ANGIOTENSINAMIDE
ANTAZOLINE
except when included in Schedule
1.
ANTIBIOTICS
except
-
(a) when
separately specified in these
Schedules;
(b) avoparcin
when packed and labelled for use as an animal feed additive;
or
(c) nisin.
ANTIHISTAMINES
(a) when
included in Schedule 1 or 2;
or
(b) when
separately specified in this
Schedule.
ANTIMALARIAL
SUBSTANCES except when separately specified in this
Schedule.
ANTIMONY,
organic compounds of, for therapeutic
use.
ANTITUBERCULAR
SUBSTANCES including isoniazid and its derivatives, para-aminosalicyclic acid
and thiacetazone except when separately
specified in these
Schedules.
APOMORPHINE
APROTININ
ARSENIC-See
THIACETARSAMIDE
ASPIRIN
when combined with caffeine paracetamol or salicylamide or any derivative of
these
substances.
ATENOLOL
ATROPINE
METHONITRATE
AURANOFIN
AZAPERONE
AZAPETINE
AZATADINE
AZLOCILLIN
AZTREONAM
BACAMPICILLIN
BACITRACIN
except
-
(a) when
specified in the Notice;
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(c) in
milk replacers for calves and starter rations for pigs, containing 100 mg/kg or
less of
antibiotic substances.
BACLOFEN
BAMIPINE
BARBITURIC
ACID and its derivatives except -
(a) when included or separately specified in the Notice; or
(b) when separately specified in this Schedule.
BECLAMIDE
BEMEGRIDE
BENACTYZINE
and other substances structurally derived from diphenylmethane with ataractic
properties when used for therapeutic
purposes.
BENDROFLUAZIDE
BENORYLATE
BENSERAZIDE
BENZAMINE,
except when included in Schedule
1.
BENZHEXOL
BENZILONIUM
BENZOCAINE,
except when included in Schedule
1.
BENZODIAZEPINE
derivatives except when separately specified in these
Schedules.
BENZOYL
PEROXIDE in preparations for external human therapeutic use, except when
included in Schedule 1 or
2.
BENZPHETAMINE
and other substances structurally derived from beta-aminopropylbenzene or
beta-aminoisopropylbenzene by substitution
in the side-chain or by ring-closure
therein (or by both such substitution and such closure) except
-
(a) when
separately spe6fied in this or any other Schedule;
or
(b) ephedrine
and pseudoephedrine in preparations exempted from Schedule
1.
BENZTROPINE
BENZYDAMINE
except when included in Schedule
1.
BENZYLPENICILLIN
(including procaine penicillin) except when specified in the
Notice.
BETAHISTINE
BETHANIDINE
BIFONAZOLE
BIPERIDEN
BISMUTH
compounds of, for human therapeutic or cosmetic use, except -
(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent or less;
(b) bismuth
oxychloride in cosmetics; or
(c) bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.
BLEOMYCIN
BORON
for human therapeutic use
-
(a) for
internal
use;
(b) in
glycerines or honeys of borax or boric
acid;
(c) in
dusting powders for paediatric use;
or
(d) as
a therapeutically active ingredient in other preparations for dermal use except
-
(i) in
antifungal preparations;
or
(ii) in
preparations containing 0.1 per cent or less of boron.
BRETYLIUM
BROMAZEPAM
BROMIDES,
inorganic, for therapeutic
use.
BROMOCRIPTINE
BROMOFORM
for therapeutic
use.
BROMPHENIRAMINE
except when included in Schedule 1 or
2.
BROMVALETONE
BUCLIZINE
except when included in Schedule 1 or
2.
BUFEXAMAC
except in preparations containing 5 per cent or less of bufexamac for external
human
therapeutic use, including
suppositories.
BUMETANIDE
BUPIVACAINE
BUPRENORPHINE
BUSPIRONE
BUSULPHAN
BUTACAINE
BUTYLAMINOBENZOATE
except when included in Schedule
1.
BUTYLCHLORAL
HYDRATE
CALCITONIN
CALCITRIOL
CALCIUM
CAR.BIMIDE for therapeutic
use.
CAMPHORATED
OIL excluding
admixtures.
CAMPHOTAMIDE
CANDICIDIN
CANINE
TICK
ANTI-SERUM
CANTRARIDIN
CAPREOMYCIN
CAPTODIAME
CAFITOPRIL
CAPURIDE
CARAMIPHEN
CARBACHOL
CARBAMAZEPINE
CARBARYL
for human therapeutic use except when included in Schedule
1.
CARBAZOCHROME
CARBENICILLIN
CARBENOXOLONE
except when included in Schedule
1.
CARBIDOPA
CARBIMAZOLE
CARBOCROMEN
CARBOPLATIN
CARBROMAL
CARDIAC
GLYCOSIDES except when separately specified in these
Schedules.
CARINDACILLIN
CARMUSTINE
CARNIDAZOLE
CEFACLOR
CEFOPERAZONE
CEFOTAXIME
CEFOTETAN
CEFOXITIN
CEFFAZIDIME
CEFFRIAXONE
CEPHACETRILE
CEPHADROXIL,
for the treatment of
animals.
CEPHALEXIN
CEPHALORIDINE
CEPHALOTHIN
CEPHAMANDOLE
CEPHAPIRIN
CEPHAZOLIN
CEPHRADINE
CHENODEOXYCHOLIC
ACID
CHLORAL
FORMAMIDE
CHLORAL
HYDRATE except
-
(a) when
included in Schedule 2;
or
(b) in
preparations for topical use containing 2 per cent or less of chloral
hydrate.
CHLORALOSE
except when specified in the
Notice.
CHLORAMPHENICOL
CHLORAZANIL
CHLORBLTTOL
in preparations for human oral use, except in preparations containing 0.5 per
cent or less of chlorbutol as a
preservative.
CHLORCYCLIZINE
CHLORDIAZEPOXIDE
CHLORMERODRIN
CHLORMEMAZOLE
CHLORMEZANONE
CHLOROFORM
for the use in
anaesthesia.
2-(4-CHLOROPHENYL)-1,2,4-TRIAZOLE
[5,la]-ISOQUINOLINE for the treatment of
animals.
CHLOROQUINE
CHLOROTHIAZIDE
CHLORPHENIRAMINE
except when included in Schedule 1 or
2.
CHLORPHENTERMINE
CHLORPROMAZINE
CHLORPROPAMIDE
CHLORTETRACYCLINE
except when specified in the
Notice.
CHLORTHALIDONE
CHLORZOXAZONE
CHOLESTYRAMINE
for human therapeutic
use.
CHYMOPAPAIN,
injection for human therapeutic
use.
CICLACILLIN
CILASTATIN
CIMETIDINE
CINCHOCAINE
CINOXACIN
CISPLATIN
CLANOBUTIN,
in injections for the treatment of
animals.
CLAVULANIC
ACID
CLEMASTINE
except when included in Schedule
2.
CLEMIZOLE
CLENBUTEROL
CLIDINIUM
CLINDAMYCIN
CLOBAZAM
CLOBETASONE-17-BUTYRATE
CLOFENAMIDE
CLOFIBRATE
CLOMIPHENE
CLOMIPRAMINE
CLOMOCYCLINE
CLONAZEPAM
CLONIDINE
CLOPAMIDE
CLOPROSTENOL
CLORAZEPATE
CLOREXOLONE
CLORPRENALINE
CLOTRIMAZOLE,
except when included in Schedule 2 or in the
Notice.
CLOXACILLIN
CLOZAPINE
CODEINE,
except when included in Schedule 1 or 2, when compounded with one or more other
therapeutically active substances -
(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or
(b) in undivided preparations containing 1 per cent or less of codeine.
COLASPASE
COLCHICINE
COLESTIPOL
for human therapeutic
use.
COLISTIN
CORTISONE
and steroid suprarenal cortical hormones, except hydrocortisone in Schedule
2.
CURARE,
TUBOCURARINE, d-TUBOCURARINE, d-TUBOCURARINEDI- METHYLETHER and all synthetic
quaternary ammonium compounds and other compounds
having curarising properties
except when separately specified in this
Schedule.
CYCLANDELATE
CYCLIZINE
CYCLOFENIL
CYCLOPENTOLATE
CYCLOPROPANE
for therapeutic
use.
CYCLOSERINE
CYCLOSPORIN
CYCRIMINE
CYPROHEPTADINE
except when included in Schedule
2.
DACARBAZINE
DANAZOL
DANTROLENE
DAPSONE
and all derivatives of
4,4-diaminodiphenylsulphone.
DEANOL
DEBRISOQUINE
DEMECARIUM
BROMIDE
DEMECLOCYCLINE
DESIPRAMINE
DESMOPRESSIN
(D.D.A.V.P.)
DETOMIDINE
DEXCULORPHENIRAMINE
except when included in Schedule 1 or
2.
DEXTROMETHORPHAN
except when included in Schedule
1.
DEXTROPROPOXYPHENE
-
(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit, or
(b) liquid
preparations containing 2.5 per cent or less of
dextropropoxyphene.
DEXTRORPHAN
DIAZEPAM
DIBENZEPIN
TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL)-AMINO)
CYCLOHEXANOL HYDRO-
CHLORIDE
MONOHYDRATE (Sputolysin) except when in Schedule
1.
DICHLORALPHENAZONE
DICHLORPHENAMIDE
DICLOFENAC
DICYCLOMINE
except when included in Schedule
1.
DIETHAZINE
DIETHYLCARBAMAZINE
for human therapeutic
use.
DIETHYLPROPION
DIFFNOXIN
in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a
quantity of atropine sulphate equivalent
to at least 5 per cent of the dose of
difenoxin.
DIFLUNISAL
DIGITALIS
and its
glycosides.
DIRYDRALAZINE
DIRYDROCODEINE
when compounded with one or more other medicaments -
(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydro- codeine,
except when included in Schedule 1.
DIHYDROSTREPTOMYCIN
except when specified in the
Notice.
DIISOPROPYLAMINE
DICHLOROACETATE
DILTIAZEM
DIMENHYDRINATE
except when included in Schedule 1 or
2.
DIMETHINDENE
except when included in Schedule
2.
DIMETHISOQUIN
except when included in Schedule
1.
DIMETHOXANATE
DIMETHYL
SULPHOXIDE for therapeutic use except when specified in the
Notice.
DINITROCRESOLS
for therapeutic
use.
DINITRONAPHTHOLS
for therapeutic
use.
DINITROPHENOLS
for therapeutic
use.
DINITROTHYMOLS
for therapeutic
use.
DINOPROST
DIPERODON
DIPHEMANIL
METHYLSULPHATF
except when included in Schedule
1.
DIPHENHYDRAMINE
except when included in Schedule 1 or.
2.
DIPHENIDOL
DIPHENOXYLATE
in preparations containing per dosage unit, 2.5 mg or less of (liphenoxylate and
a quantity of atropine sulphate equivalent
to at least 1 per cent of the dose of
diphenoxylate.
DIPHENYLPYRALINE
except when included in Schedule 1 or
2.
DIPIVEFRIN
DIPYRIDAMOLE
DISOPHENOL
DISPYRAMIDE
DISULFIRAM
for therapeutic
use.
DITHIAZANINE
except when specified in the
Notice.
DOBUTAMINE
DOMPERIDONE
DOPAMINE
DOTHIEPIN
DOXAPRAM
DOXEPIN
DOXORUBICIN
DOXYCYCLINE
DOXYLAMINE
except when included in Schedule 1 or
2.
DROPERIDOL
DROSTANOLONE
ECONAZOLE
except when included in Schedule 2 or in the
Notice.
EDETIC
ACID for human therapeutic use in preparations for injection or
infusion.
EMETINE
except in preparations containing 0.2 per cent or less of
emetine.
ENALAPRIL
EPHEDRINE
except
-
(a) when
included in Schedule 1 or
2;
(b) in
preparations for topical use containing 1 per cent or less of ephedrine;
or
(c) when compounded with one or more other therapeutically active substances in liquid preparations for internal use containing 10 mg or less of ephedrine per recommended dose, other than preparations for stimulant, appetite suppression or weight control purposes.
ENFLURANE
for therapeutic
use.
EPICILLIN
EPIRUBICIN
ERGOT
ERYTHROMYCIN
except
-
(a) when
specified in the Notice;
(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances; or
(c) in milk replacers for calves or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.
ETHACRYNIC
ACID
ETHAMBUTOL
ETHAMIVAN
ETHCHLORVYNOL
ETHER
for use in
anaesthesia.
ETHINAMATE
ETHOGLUCID
ETIiOHEPTAZINE
except when included in Schedule
1.
ETHOPROPAZINE
ETHOXZOLAMIDE
ETHYL
CHLORIDE for inhalation
anaesthesia.
ETHYLMORPHINE
when compounded with one or more other medicatments -
(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b) in undivided preparations with a concentration of more than 2.5 per cent of ethylmorphine.
except when included in Schedule 1.
ETHYLOESTRENOL
ETIDOCAINE
ETIDRONATE
except in toothpastes and gel containing 1 per cent or less of
etidronate.
ETILEFRIN
HYDROCHLORIDE
ETOPOSIDE
ETRE'NNATE
FELYPRESSIN
FENCAMFAMIN
FENFLURAMINE
FENOPROFEN
FENOTFROL
except when included in Schedule
2.
FENPIPRAMIDE
FENPIPRANE
FENPROSTALENE
FLAVOPHOSPEOLIPOL
except -
(a) when specified in the Notice; or
(b) in animals feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
FLECAINIDE
FLUCLOXACILLIN
FLUCYTOSINE
FLUFENAMIC
ACID
FLUNISOLIDE
FLUNITRAZEPAM
FLUNIXIN
MEGLUMINE for the treatment of
animals.
FLUORIDES
in preparations for human ingestion except when included in Schedule
1.
FLUOROURACIL
and other substances structurally derived from uracil with cytotoxic properties
when used for therapeutic
purposes.
FLUOXYMESTERONE
FLUPHENAZINE
FLUPROSTENOL
FLURAZEPAM
FLUROXENE
for inhalation
anaesthesia
FLUSPIRILENE
FOLLICLE
STIMULATING HORMONE (See also
gonadotrophins)
FRAMYCETIN
FRUSEMIDE
FUSIDIC
ACID
GALANTHAMINE
GALLAMINE
GEMEPROST
GENTAMCIN
GLIBENCLAMIDE
GLIBORNURIDE
GLICLAZIDE
GLUCAGON
GLUTETHIMIDE